Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?

Main Article Content

M. Rossini *
O Viapiana
G. Orsolini
E. Fracassi
L. Idolazzi
D. Gatti
S. Adami
M. Govoni
(*) Corresponding Author:
M. Rossini | maurizio.rossini@univr.it

Abstract

Golimumab is an anti-TNF monoclonal antibody administred subcutaneously once a month and produced with an innovative technology that minimizes immunogenicity. This paper reviews and updates the main studies on the efficacy, safety and pharmacoeconomic aspects of treatment with golimumab of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis.

Downloads month by month

Downloads

Download data is not yet available.

Article Details

Most read articles by the same author(s)